Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 250, Issue 5, 2012, Pages 713-720

  Erckens, R J ^a   Mostard, R L M ^a,b   Wijnen, P A H M ^a   Schouten, J S ^a   Drent, M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Sittard Geleen Heerlen   (Netherlands)

Author keywords

Adalimumab; Anti TNF alpha treatment; Sarcoidosis; Uveitis

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CARBON MONOXIDE; DIPEPTIDYL CARBOXYPEPTIDASE; INTERLEUKIN 2; METHOTREXATE; PREDNISOLONE;

ADJUVANT THERAPY; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; LUNG FUNCTION; LUNG SARCOIDOSIS; MALE; PAPILLITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RATING SCALE; RECURRENT DISEASE; REFRACTORY CHRONIC NON INFECTIOUS UVEITIS; RETINA MACULA EDEMA; RETINA VASCULITIS; SCORING SYSTEM; TREATMENT DURATION; UVEITIS;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHRONIC DISEASE; FATIGUE; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; LUNG; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; SARCOIDOSIS; TOMOGRAPHY, OPTICAL COHERENCE; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS, POSTERIOR; YOUNG ADULT;

EID: 84862863465     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-011-1844-0     Document Type: Article

References (43)

1. Rothova A (2000) Ocular involvement in sarcoidosis. Br J Ophthalmol 84: 110-116
2. Kosmorsky GS, Meisler DM, Rice TW, Meziane MA, Lowder CY (1998) Chest computed tomography and mediastinoscopy in the diagnosis of sarcoidosis- associated uveitis. Am J Ophthalmol 126: 132-134
3. Iannuzzi MC, Rybicki BA, Teirstein AS (2007) Sarcoidosis. N Engl J Med 357: 2153-2165
4. Herbort CP, Rao NA, Mochizuki M (2009) International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS). Ocul Immunol Inflamm 17: 160-169
5. Martin TM, Doyle TM, Smith JR, Dinulescu D, Rust K, Rosenbaum JT (2003) Uveitis in patients with sarcoidosis is not associated with mutations in NOD2 (CARD15). Am J Ophthalmol 136: 933-935
6. Dana MR, Merayo-Lloves J, Schaumberg DA, Foster CS (1996) Prognosticators for visual outcome in sarcoid uveitis. Ophthalmology 103: 1846-1853
7. Ardoin SP, Kredich D, Rabinovich E, Schanberg LE, Jaffe GJ (2007) Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol 144: 844-849
8. Dev S, McCallum RM, Jaffe GJ (1999) Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology 106: 111-118
9. Baughman RP, Lower EE, Drent M (2008) Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoidosis Vasc Diffuse Lung Dis 25: 76-89
10. Baughman RP, Costabel U, du Bois RM (2008) Treatment of sarcoidosis. Clin Chest Med 29: 533-548, ix-x
11. Elfferich MD, Nelemans PJ, Ponds RW, Vries JD, Wijnen PA, Drent M (2010) Everyday Cognitive Failure in Sarcoidosis: the Prevalence and the Effect of Anti-TNF-α- treatment. Respiration
12. Baughman RP, DrentM, KavuruM, Judson MA, Costabel U, du Bois R, Albera C, Brutsche M, Davis G, Donohue JF, Muller-Quernheim J, Schlenker-Herceg R, Flavin S, Lo KH, Oemar B, Barnathan ES (2006) Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174: 795-802
13. Baughman RP, Lower EE (2001) Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 18: 70-74
14. Galor A, Perez VL, Hammel JP, Lowder CY (2006) Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 113: 2317-2323
15. Hale S, Lightman S (2006) Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine 33: 231-237
16. Sobrin L, Kim EC, Christen W, Papadaki T, Letko E, Foster CS (2007) Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 125: 895-900
17. Petropoulos IK, Vaudaux JD, Guex-Crosier Y (2008) Anti-TNFalpha therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital. Klin Monbl Augenheilkd 225: 457-461
18. Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM (2005) Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 89: 533-536
19. Takase K, Ohno S, Ideguchi H, Uchio E, Takeno M, Ishigatsubo Y (2011) Successful switching to adalimumab in an infliximaballergic patient with severe Behçet disease-related uveitis. Rheumatol Int 31: 243-245
20. Seiderer J, Brand S, Dambacher J, Pfennig S, Jurgens M, Goke B, Ochsenkuhn T (2007) Adalimumab in patients with Crohn's disease-safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther 25: 787-796
21. Simonini G, Taddio A, Cattalini M, Caputo R, De Libero C, Naviglio S, Bresci C, Lorusso M, Lepore L, Cimaz R (2010) Prevention of flare recurrences in childhood refractory chronic uveitis: an open-label comparative study of Adalimumab versus Infliximab. Arthritis Care Res (Hoboken)
22. Kamphuis L WL-T, Dik W, et al. (2011) Efficacy of adalimumab in chronically active and symptomatic sarcoidosis patients. American Journal of Respiratory and Critical Care Medicine (in press)
23. Callejas-Rubio JL, Ortego-Centeno N, Lopez-Perez L, Benticuaga MN (2006) Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol 25: 596-597
24. Field S, Regan AO, Sheahan K, Collins P (2010) Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to etanercept. Clin Exp Dermatol 35: 795-796
25. Philips MA, Lynch J, Azmi FH (2005) Ulcerative cutaneous sarcoidosis responding to adalimumab. J Am Acad Dermatol 53: 917
26. Heffernan MP, Smith DI (2006) Adalimumab for treatment of cutaneous sarcoidosis. Arch Dermatol 142: 17-19
27. Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, Eklund A, Kitaichi M, Lynch J, Rizzato G, Rose C, Selroos O, Semenzato G, Sharma OP (1999) ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 16: 149-173
28. Bartalesi F, Vicidomini S, Goletti D, Fiorelli C, Fiori G, Melchiorre D, Tortoli E, Mantella A, Benucci M, Girardi E, Cerinic MM, Bartoloni A (2009) QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 33: 586-593
29. Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140: 509-516
30. Mostard RL, Voo S, van Kroonenburgh MJ, Verschakelen JA, Wijnen PA, Nelemans PJ, Erckens RJ, Drent M (2011) Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis. Respir Med 2011 Sep 5 [Epub ahead of print]
31. de Kleijn WP, Elfferich MD, De Vries J, Jonker GJ, Lower EE, Baughman RP, King TE Jr, Drent M (2009) Fatigue in sarcoidosis: American versus Dutch patients. Sarcoidosis Vasc Diffuse Lung Dis 26: 92-97
32. Akova YA, Foster CS (1994) Cataract surgery in patients with sarcoidosis-associated uveitis. Ophthalmology 101: 473-479
33. Sandborn WJ, Hanauer S, Loftus EV Jr, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R (2004) An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 99: 1984-1989
34. Baughman RP (2007) Tumor necrosis factor inhibition in treating sarcoidosis: the American experience. Revista Portuguesa de Pneumonologia 13: S47-S50
35. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT (2006) The PREMIER study: A multicenter, randomized, doubleblind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54: 26-37
36. Breban M, Ravaud P, Claudepierre P, Baron G, Henry YD, Hudry C, Euller-Ziegler L, Pham T, Solau-Gervais E, Chary-Valckenaere I, Marcelli C, Perdriger A, Le Loet X, Wendling D, Fautrel B, Fournie B, Combe B, Gaudin P, Jousse S, Mariette X, Baleydier A, Trape G, Dougados M (2008) Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus ondemand treatment. Arthritis Rheum 58: 88-97
37. van Riel PL, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, Freundlich B, MacPeek D (2006) Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis 65: 1478-1483
38. Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP, Dijkmans BA, Aarden L (2005) Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 64: 704-707
39. Gratacos J, Casado E, Real J, Torre-Alonso JC (2007) Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. Ann Rheum Dis 66: 493-497
40. Stone MA, Payne U, Pacheco-Tena C, Inman RD (2004) Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. Ann Rheum Dis 63: 84-87
41. Louis E, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Malaise M, Belaiche J (2002) A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with ?308 TNF gene polymorphism. Scand J Gastroenterol 37: 818-824
42. Sweiss NJ, Barnathan ES, Lo K, Judson MA, Baughman R (2010) C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 27: 49-56
43. Keijsers RG, Verzijlbergen JF, van Diepen DM, van den Bosch JM, Grutters JC (2008) 18 F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 25: 143-149